Cadbury Buys Adams in a Sweet Deal
Cadbury Schweppes PLC is a confectionary and beverage company headquartered in
London, England. Cadbury Schweppes (Cadbury) acquired Adams Inc., a chewing gum
manufacturer, from Pfizer Corporation in 2003 for $4.2 billion. The acquisition enables
Cadbury to gain access to new markets, especially in Latin America. The purchase also
catapulted Cadbury to the top spot in the global confectionary market. Adams’s major
brands are in the fastest growing segments of the global market and complement
Cadbury’s existing chocolate business.
Cadbury bought 100 percent of the business of the Adams Division of Pfizer. The
decision whether to transfer assets or stock depended on which gave Cadbury and
Pfizer optimum tax advantages. Furthermore, many employees had positions with both
the parent and the operating unit. In addition, the parent supplied numerous support
services for its subsidiary. While normal in the purchase of a unit of a larger company,
this purchase was complicated by Adams operating in 40 countries representing 40
legal jurisdictions.
Cadbury and Pfizer representatives agreed on a single asset and stock sale and purchase
agreement (i.e., the master agreement), which transferred the relevant U.S. assets and
stock in Adams’s subsidiaries to Cadbury. The master agreement contained certain
overarching terms, including closing conditions, representations and warranties,
covenants, and indemnification clauses that applied to all legal jurisdictions. However,
the master agreement required Pfizer or Adams to enter into separate local
“implementation” agreements. This was done to complete the transfer of either Adams’s
assets in non-U.S. jurisdictions or shares in non-U.S. Adams’s subsidiaries to local
Cadbury subsidiaries depending on which provided the most favorable tax advantages
and where necessary to accommodate differences in local legal conditions. The parties
entered into more than 20 such agreements to transfer asset and stock ownership. All
the agreements used the master agreement as a template. Written in English, the various
contracts were governed by New York law, the state in which Pfizer is headquartered,
except where there was a requirement that the law governing the contract be that of the
local country.
A team of 5 Cadbury in-house lawyers and 40 outside attorneys conducted the legal
review. Cadbury staff members carried out separate environmental due diligence
exercises, because Adams had long-standing assets in the form of plant and machinery
in each of 22 factories in 18 countries. Cadbury filed with antitrust regulators in a
number of European and non-European countries, including Germany, the Czech
Republic, Turkey, Greece, Italy, Portugal, Spain, the United Kingdom, South Africa,
and Brazil. The requirements varied in each jurisdiction. It was necessary to obtain
regulatory clearance before closing in countries where prenotification was required. The
master agreement was conditional on antitrust regulatory approval in the United States,
Canada, and Mexico, Adams’s largest geographic markets.
Cadbury wanted all 12,900 Adams employees across 40 countries to transfer to it with
the business. However, because not all of them were fully dedicated Adams employees
(i.e., some had both Adams and Pfizer functions), it was necessary to determine on a
site-by-site basis which employees should remain with Pfizer and which should transfer
to Cadbury. Partly due to the global complexity of the deal, the preclosing and closing